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A B S T R A C T 24 
On demand manufacturing of patient-specific oral doses provides significant advantages to patients and 25 
healthcare staff. Several 3D printing (3DP) technologies have been proposed as a potential digital 26 
alternative to conventional manufacturing of oral tablets. For additive manufacturing approach to be 27 
successful for on-demand preparation, a facile process with minimal preparation steps and training 28 
requirements is needed. A novel hybrid approach to the 3D printing process is demonstrated here based 29 
on combined solvent and heating elements/factors/aspects to facilitate extrusion. The system employed 30 
a moderate elevated temperature range of (65-100 oC), a brief drying period, and a simple set-up. In this 31 
approach, a compact powder cylinder is used as a pharmaceutical ink to be extruded in a temperature-32 
controlled metal syringe. The process proved compatible with hygroscopic polymers [Poly(vinyl 33 
alcohol (PVA)  and poly(vinyl pyridine) (PVP)] and a number of pharmaceutical fillers (lactose, 34 
sorbitol and mannitol). The fabricated tablets demonstrated compendial acceptable weight and content 35 
uniformity as well as mechanical resistance. In vitro drug release of theophylline from 3D printed tablets 36 
was dependant on the nature of the polymer and its molecular weight. This reported approach offers 37 
significant advantages compared to other 3DP technologies:  simplification of pre-product, the use of a 38 
moderate temperature range, a minimal drying period, and avoiding the use of mechanically 39 
complicated direct extruder machinery. In the future, we envisage the use of this low-cost and facile 40 
approach to fabricate small batches of bespoke tablets.  41 
 42 
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1. Introduction 45 
The demand for personalised therapies has been increasing over the last decade due to the most recent 46 
advances in pharmacogenomics and stratified medicine. This has allowed complex diseases and their 47 
biological mechanisms to be better understood and to develop more effective strategies to predict and 48 
prevent illnesses, as well as to treat them [1-3]. Such developments in personalised therapies induced 49 
the interest in developing digital solutions for small batch production of patient-specific dosage forms 50 
[4, 5]. 51 
The past few years have witnessed a growing interest in 3D printing (3DP) as an on-demand 52 
manufacturing tool for small batch manufacturing, age-specific products in paediatrics [6, 7] and 53 
meeting the needs of polypharmacy [8-10]. With several 3DP technologies available, fused deposition 54 
modelling (FDM) 3DP has been proposed as a low-cost solution for the fabrication of patient specific 55 
dosage forms [11-16]. The FDM technology offers significant potential advantages including process 56 
simplicity, the lack of drying or finishing steps and potential of mass production of low-cost 57 
pharmaceutical printers and ink cartridges. However, FDM 3DP has to overcome some significant 58 
technical challenges to wider uptake and adoption as it exposes the starting pharmaceutical material to 59 
two sequential-thermal processes (when hot melt extrusion-based filaments are used as a feed) [5, 17], 60 
engineering and optimizing the ‘feedability’ of the filament [18-20], as well as minimising the risk of 61 
mechanical and physical modification of the filament during storage prior to on-demand 3DP. Such 62 
challenges might hinder or slow down the advances of this important technology in the pharmaceutical 63 
market. Several modifications to FDM 3DP have been applied to reduce the thermal stress of the 64 
printing process. For instance, Okwuosa et al. [21] pioneered the use of poly(vinyl alcohol) (PVA) to 65 
reduce the printing temperature to as low as 110 oC. Other adaptations have further reduced the printing 66 
temperature by employing polymers with low glass transition temperature (90 oC) [22], by the 67 
replacement of filaments with softer extruded polymer strands as low as 54 oC  [23, 24], or  by using 68 
water in filament preparation step as a temporary plasticiser [9].  69 
Extrusion-based 3DP has been proposed as an alternative method of manufacture of tablets. While the 70 
former obviates the need of engineering and stabilising filaments, it faces a major challenge of extruding 71 
a material into solidifying structures in acceptable time. The extrusion of semi-solids (drug suspension) 72 
at room temperature can be employed using a printer often used in tissue engineering [10, 25-27]. The 73 
process involves the use of powder slurry in a significant amount of water [25, 27, 28] or ethanol [29]. 74 
By using thermally heated piston-operated syringe (<70 oC), extrusion-based 3D printing was also 75 
employed to produce solid self-micro-emulsifying drug delivery systems [30] and chewable jelly-like 76 
tablets [31]. Alternatively, extrusion can be carried out at high temperature with built-in screw extruder 77 
[32]. However, this promising technology must overcome several barriers such balancing efficient 78 
extrusion process with the use of typically heavy machinery (hot extruder motor assembly) that are 79 
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often needed to provide sufficient torque for extrusion as well as providing easy solution for batch-to-80 
batch cleaning of complex-shaped screws in the extruder assembly. 81 
In this paper, we present the use of a novel alternative approach of temperature and solvent facilitated 82 
extrusion-based 3D printing as a facile manufacturing process suitable for extemporaneous preparations 83 
near to the patient. This hybrid approach of combining solvent and elevated temperature for fabrication 84 
of oral tablets uses an extrusion-based system that is delivered by simple metal syringe. We envisage 85 
the use of a compressed powder cylinder as a pharmaceutical ink. 86 
2. Materials and methods 87 
2.1 Materials 88 
Theophylline was purchased from Acros Organics (UK). Three grades of Poly(vinyl alcohol) were used: 89 
PVA 20-30K and PVA 83K were supplied from Fisher scientific UK, and PVP Parteck® MXP [MXP, 90 
k75] was donated by Merck (Darmstadt, Germany). Polyvinylpyrrolidone (PVP, Plasdone™ K-29/32) 91 
was donated by Ashland (UK). Sodium stearyl fumarate (PRUV) was donated by JRS (Germany) and 92 
sorbitol was purchased from Merck (Parteck SI, Germany). D-mannitol, lactose and HPLC gradient 93 
grade acetonitrile were obtained from Fisher Scientific Ltd (Loughborough, UK). 94 
2.2 Preparation for the feed 95 
The model drug (theophylline) and polymer (PVA 20-30K, Parteck [MXP, k75], PVA 83K, PVP) in 96 
addition to other additives were accurately weighed and thoroughly mixed via shear mixing using Krups 97 
F20342 grinder (Germany). The breakdown of each blend compositions is detailed in Table 1. Initially, 98 
sorbitol was selected as a primary plasticiser as established plasticising capacity for PVA matrixes [33, 99 
34] and structure enhancer. Lactose and D-mannitol were added for common use as highly soluble 100 
structure enhancers [35, 36]. Preliminary screening work indicated that material flow from the syringe 101 
could be significantly enhanced by the addition of sodium stearyl fumarate at 5% as a lubricant. Further 102 
increase in of sodium stearyl fumarate led to incomplete 3D printing due to poor adhesion of the tablet 103 
to the printing plate or weak fusion of the printed layers. To approximately 10 g of each blend, an 104 
additional 2 g of deionised water was added to each formulation and mixed for an additional 30 seconds. 105 
Each blend was compressed using a 12 mm diameter metal syringe (Hyrel 3D, Atlanta, USA) to form 106 
10 cm height cylinder. The compressed cylinder (based on 12 g of polymer blend + water) were stored 107 
in plastic polybag and used as feed for the 3D printing process (Section 2.3).  108 
In order to assess the impact of the filler nature, sorbitol was replaced with an equivalent amount of D-109 
mannitol or lactose. To assess the impact of different plasticiser concentrations of sorbitol: 15%, 20% 110 
and 25% (w/v) were assessed. Table 1 provides a summary of all formulations prepared using TASFEX 111 
technology. 112 
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2.3 Tablet design and TASFEX 3D printing 113 
The tablets were designed in a cylindrical shape using Autodesk® 3ds Max Design 2019 (Autodesk, 114 
Inc., USA). The designs were then imported to the Slic3r (version 1.3) software in stereolithographic 115 
(STL) format and converted to gcode files using the settings specified as: layer thickness 0.3 mm, first 116 
layer thickness 0.5 mm, speed perimeters 50%, infill speed 7 mm/sec, travel speed 15 mm/sec, first 117 
layer build speed 7 mm/sec, and nozzle diameter 1.19 mm. 118 
A Hyrel System 30M (Hyrel 3D, Atlanta, USA) equipped with a VOL-25 (Volcano) modular head and 119 
a 16-gauge stainless steel tip was used to fabricate the tablets. The default glass plate was replaced with 120 
an acrylic sheet for better adhesion to the building plate. The settings inserted in the Repetrel software 121 
(version 3.0) for the printer head were: nozzle diameter: 1.194, thickness of layer z: 0.3 mm, motor 122 
pulses rate: 2.3 pulses/nL, infill percentage: 100% and a material flow multiplier: 1.2. Following the 123 
printing process the tablets were dried for 2 hours at 50 oC using Binder Drying chamber 9010 (Binder 124 
GmbH, Germany). Prior to printing, the compressed cylinder was placed in the heated syringe and 125 
heated at processing temperature for 30 min. 126 
2.4 Thermal analysis 127 
Samples of the raw materials, dry physical mixture and 3D printed tablets were analysed by differential 128 
scanning calorimetry (DSC) and thermogravimetric analysis (TGA). DSC Q2000 (TA Instruments, 129 
Elstree, UK) was used to assess the thermal behaviour of the samples: approximately 5 mg samples 130 
were scanned from 0 to 300°C using at a heating rate of 10°C/min and a nitrogen purge of 50 mL/min 131 
using standard aluminium pans and lids. TGA Q500 (TA Instruments, Elstree, Hertfordshire, UK) was 132 
used to analyse approximately 10 mg of each material filled in platinum pans. Samples were heated at 133 
a rate of 10°C/min from 25°C to 500°C with a nitrogen purge of 40:60 ml/min for sample: furnace 134 
respectively. TA Universal analysis software (v 4.5A, TA Instruments, Elstree, UK) was used to analyse 135 
data for both DSC and TGA. 136 
2.5 X-Ray Diffractometry (XRD) 137 
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to assess the 138 
physical form of the model drug and fillers within the 3D printed tablets. Samples were scanned from 139 
2Theta = 5° to 50° using 0.01° step width and a 1.25 s time count. The divergence slit was 1 mm and 140 
the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a voltage of 141 
30 kV. Filament emission was 10 mA using a scan type coupled with a theta/theta scintillation counter 142 
over 60 min. 143 
2.6 Water contents 144 
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The water content was determined using Karl Fischer method (KF) using Metorhm 870 KF Titrino plus 145 
(Metrohm UK Ltd., Runcorn, UK). Each ingredient and dried 3D printed tablets has been measured 146 
sample (500 mg) accurately weight using Mettler Toledo analytical balance (Mettler, Germany). The 147 
water content was calculated via Titrino plus software (Metrohm UK Ltd., Runcorn, UK) or end-point 148 
was utilized for % water content calculation.  149 
 150 
2.7 Dimensions and mechanical properties of the 3D printed tablet 151 
To assess the mechanical resistance of 3D printed tablets, the 3D printed tablets were assessed 152 
using Agilent 200 Tablet Hardness Tester (Agilent Technologies). Measurements of resistance 153 
to crushing of the tablet were carried out in triplicates for each selected formulation. The 154 
friability of 3D printed tablets (n=10) were accurately weighed, placed in the apparatus drum 155 
of Agilent Dual-drum Friability Tester 250 (Agilent Technologies) and rotated 100 times. The 156 
dimensions of 3D tablet dimensions were assessed using eSYNic Digital Vernier digital 157 
calliper (eSYNic, China). A randomly selected 10 3D printed tablets from each selected 158 
formulation were and weighed. The average mass, standard deviation and percentage deviation 159 
from average mass were determined for each batch.  160 
2.8 Analysis of drug contents using HPLC 161 
Theophylline content of the tablets was assessed using an Agilent 1260 series UV-HPLC 162 
(Agilent Technologies, Germany) with XTerra RP 18 column (150 × 4.6 mm, 5 μm particle 163 
size) (Waters, Ireland) as previously reported [21]. The mobile phase (86:7:7 volume ratio of 164 
10 mM ammonium acetate buffer: methanol: acetonitrile) was applied at flow rate of 1 mL/min 165 
at temperature 40°C. Samples were injected  (5 μL) and the run time of 7 min and analysis was 166 
carried out at a wavelength of 272 nm. 167 
2.9 Scanning Electron Microscopy (SEM) 168 
The morphology and cross-section of the tablets were assessed using a JCM-6000 plus 169 
NeoScope™ microscope (Jeol, Tokyo, Japan) at 10 kV. All samples were gold coated using a 170 
JFC-1200 Fine Coater (Jeol, Tokyo, Japan). The images were collected using Image J software 171 
(v 1.2.0., Tokyo, Japan). 172 
2.10 In vitro disintegration and dissolution  173 
In vitro disintegration and drug release studies. Tablet disintegration was carried out using an 174 
Erweka ZT220 disintegration testing apparatus (Erweka GmbH, Heusenstamm, Germany). 175 
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Three tablets were randomly selected, weighed and each placed in a basket rack assembly of 176 
six cylinders and weights were added on the top of the tablets. The basket rack assembly was 177 
then immersed into a beaker containing 0.1M hydrochloric acid at 37 ̊C. The exact time for all 178 
tablets to fully leave the mesh was visually noted. 179 
In vitro drug release testing. The impact of the tablet’s design on the release pattern of the 3D 180 
printed tablets was assessed using a USP II dissolution test paddle apparatus (Erweka GmbH, 181 
Germany). The dissolution study was conducted in 900 mL of 0.1 M hydrochloric acid (pH 182 
1.2) at 37 ± 0.5 °C and with paddle speed of 50 rpm. The amount of released theophylline was 183 
determined at 5 min intervals by UV/VIS spectrophotometer (PG Instruments Limited, UK) at 184 
a wavelength of 272 nm and a path length of 1 mm. Data were analysed using IDISis software 185 
version 2012 (Automated Lab, Berkshire, UK). 186 
3. Results and Discussion 187 
The manufacturing equipment required for TASFEX is illustrated in Fig. 1. Here, a 188 
cylinder of compressed pharmaceutical ink is loaded into a metal syringe and water is added. 189 
The material is pressurised under a moderately elevated temperature (50-100oC) using the 190 
support of a piston stepper motor with a built-in gear to increase the load-to-motor inertia ratio 191 
and to reduce motor oscillation. In this arrangement, the starting material can be loaded as a 192 
compressed powder in a form of cylinder (12mm diameter x 60 mm height) to produce a set 193 
number of tablets. The simplicity of this set-up and the lack of screw parts of complicated 194 
design that necessitate special cleaning protocols make it particularly suitable for dispensing 195 
bespoke doses in a hospital setting. In the future, it is possible to employ low-cost thermally 196 
conductive disposable syringes to eliminate the risk of cross-contamination for production of 197 
multiple batches. 198 
Initially, tablet extrusion was carried out without the inclusion of water. However, no 199 
material flow was possible at the process temperature of 90oC. Preliminary investigations 200 
indicated that a significant increase of the plasticiser (sorbitol) ratio allow significant material 201 
flow. However, this approach led to the formation of a highly flexible matrix that was not 202 
suitable for oral tablet structure (data not shown). Here, we adapted the solution of adding water 203 
as a temporary plasticiser as previously reported [9]. In this approach, water was added to the 204 
final powder blends to facilitate the printing of these tablets. Table 1 shows the content of 205 
different formulations which were prepared using the novel TASFEX system. The inclusion of 206 
water allowed a sufficient material flow from the temperature-controlled metal syringe and 207 
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enabled 3D printing at relatively low temperature (65-100oC). The concentration of plasticiser 208 
(sorbitol) was varied in the presence of a fixed amount of water and the fabrication process was 209 
successful in a sorbitol concentration range of 15-25%w/v. A filler ratio of 20% was chosen, 210 
as it yielded the most visually desirable structure of a smooth surface and a consistent filling. 211 
In order to assess the suitability of the process to different fillers, two additional sugars (lactose 212 
and D-mannitol) were incorporated in the formulation which yielded well-structured tablets 213 
demonstrating the versatility of the process (Figs. 2 a1-d1).  214 
SEM images indicated the formation of relatively smooth upper surface of tablets (Figs. 215 
2 a2-d2). Each layer was composed of 300m layers (Figs. 2 a3-d3). Interestingly, the SEM 216 
images of the cross-sections of the tablet indicated that PVA-based tablet made with lactose 217 
and D-mannitol showed individual layers, tablets that are based on PVA-sorbitol and PVP-218 
lactose demonstrated a more cohesive structure with seamless lines between the deposited 219 
layers (Figs. 2 a4-d4). 220 
The TGA thermograph showed that all molecules were stable at the processing 221 
temperature (100 oC) (Fig. 3). In all these examples, the 3D printed tablets appeared to lose 222 
approximately <3% of their total mass due to moisture evaporation. The magnitude of this loss 223 
is significantly lower in the powder blend (physical mixture) in comparison to the 3D printed 224 
tablets, indicating that these tablets retained some level of water.  To assess the impact of drying 225 
process, Karl Fisher analysis was used to assess the percentage of moisture content in the dried 226 
3D printed tablets Table S1 (Supplementary data). The analysis indicated that drying process 227 
yielded 3D printed tablet (F2) of minimal water contents (<0.5%). While this approach offers 228 
advantages over using highly diluted drug and additive slurry [25, 27, 28]  and producing 229 
relatively solid structure before any additional drying process, the elevated processing 230 
temperature might be less suitable for thermally labile drug.  231 
DSC thermographs indicated that onset of melting points of sorbitol, lactose and 232 
mannitol of 91, 140 and 164 oC respectively [37]. The physical blend indicated the presence of 233 
these peaks in their corresponding thermographs. When the 3D printed tablets were tested, 234 
minor or no endothermal peak were seen in sorbitol tablets (n=3) (Fig. 4a), whilst the 235 
endotherm melting peaks was clearer in both D-mannitol and lactose thermographs (Figs. 4b, 236 
4c). The role of sorbitol as a plasticiser has been described before in PVA matrix [38]. The 237 
significant ability of this sugar to plasticise PVA matrix was directly related to its ability to 238 
form hydrogen bonds with -hydroxyl groups of PVA structure as well as water molecules, 239 
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hence enhancing the polymer ability to retain water [39]. These findings suggest that lactose 240 
and mannitol might be less miscible within the PVA matrix and therefore a significant portion 241 
of the sugar were in the crystalline form within the 3D printed structure.  242 
XRD intensity patterns indicated that sorbitol (as received) has distinctive intensity 243 
peaks of 2Theta = 12.12 O and 19.1O (Fig. 5a). While these peaks appeared in the physical 244 
mixture, they were absent in the XRD patterns of the 3D printed tablets, and hence confirmed 245 
that sorbitol was mainly in the amorphous form within the 3D printed tablet matrix. However, 246 
in the case of lactose (2Theta = 16.4o) and D-mannitol (2Theta = 16.9, 35.9 and 44.13o) 247 
suggesting that both fillers were in crystalline form (Figs. 5 b and c). This could be the result 248 
of applying processing temperatures (90-100 oC) that reached the melting point of sorbitol (91 249 
oC), but below the melting point of lactose and D-mannitol (140 and 164 oC).  The presence of 250 
both lactose and D-mannitol in crystalline form might have favoured the formation of tablets 251 
of improved physical structure. XRD patterns also indicated that theophylline was in crystalline 252 
form with the presence of peaks 2Theta = 6.8 and 12.3o (Figs. 5 a, b and c).  253 
The extrudability of the polymeric matrix can be linked to its rheological behaviour. 254 
The complex viscosity of the material were observed to drop down when polymer was blended 255 
with other non-melting additives [40, 41]. It was noticed that the glass transition temperature 256 
(Tg) dropped with the decrease in the complex viscosity of the mixture [41]. In another 257 
example, the addition of sugar (lactose, mannitol, or sorbitol) to polyethylene glycol matrix 258 
was noticed to help in controlling the complex viscosity [42] by maintaining a shear-thinning 259 
behaviour, which is required for extrudability followed by solidification at room temperature. 260 
In order to demonstrate the versatility of the presented method to accommodate 261 
different polymer species, pyrrolidine derivative (PVP) was also tested as a polymer species 262 
and yielded a tablet (Fig. 2f). Physical analysis indicated that lactose was in the crystalline 263 
form (endotherm of melting peak onset at 140 oC and an intensity peak XRD patterns (2Theta 264 
= 16.4o) (Fig. 6). However, when less hydrophilic polymers (e.g. Eudragit E, Eudragit L, 265 
Eudragit EPO or HPC SL) were applied in the same formulation, the solvent (water) separated 266 
from the powder bulk (Eudragit E and HPC SL) or the extruded filaments from hot nozzle 267 
failed to fuse together following application from the nozzle to yield a cohort 3D structure. 268 
This demonstrates that the reported TASFEX approach is more suitable for polymer systems 269 
with functional groups of hydrophilic properties which are able to retain water within the 270 
polymeric matrix and facilitates multilayer adhesion upon hydration.  271 
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Four selected formulations were selected for further tablet characterization as detailed 272 
in Table 2.  The pharmacopeial tests indicated a generally long disintegration time for 3D 273 
printed tablet structures. This is in agreement with recent reports in which polymer-rich 3D 274 
printed structures showed slow in vitro dissolution profiles despite the use of fast-dissolving 275 
polymers that are typically used for immediate release preparations [32, 43]. This in contrast 276 
to immediate release and fast disintegrating tablets are often composed with large portion of 277 
disintegrating fillers. The disintegration time was reported to be much shorter for the D-278 
mannitol based tablet (Table 2) compared to other fillers. Such disintegrants effect of D-279 
mannitol has been previously reported [44, 45].  280 
Despite the relatively large nozzle size used for the extrusion of polymeric structure 281 
(1.2 mm), the majority of fabricated tablets illustrated highly reproducible dimensions and 282 
weight (Table 2). The tablets also demonstrated pharmaceutically acceptable mechanical 283 
properties of friability (<1%). The in vitro dissolution of the fabricated tablets is shown in Fig. 284 
7. Modifying the percentage of sorbitol in the PVA matrix appeared to have a limited impact 285 
of the rate of theophylline release (Fig. 7a). The nature of dissolution seems also to be 286 
independent of the nature of the plasticiser sugar (Fig. 7b). This indicates that the theophylline 287 
release was mainly dominated by the erosion of PVA. As the dissolution medium penetrate 288 
through PVA matrix, drug release will take place through the erosion of the hydrate matrix and 289 
diffusion through the polymeric chain networks [46]. When other PVA grades with higher and 290 
lower molecular weight were incorporated in the tablets, drug release was dependent on the 291 
molecular weight of the PVA grade (Fig. 7c). This observation can be attributed to the 292 
reduction of water diffusion co-efficient with increased molecular weight of PVA [47]. On the 293 
other hand, the use of PVP as a base for 3D printed tablets resulted in theophylline release of 294 
>85% at 45 min in the gastric medium (Fig. 7d) and was compatible with the BP pharmacopeia 295 
for immediate release theophylline tablets. The fast dissolution rate from PVP matrix could be 296 
attributed to its solubility enhancing properties [48, 49]. Drug release from 3D printed tablets 297 
seemed to mimic that from tablets produced via FDM 3D printing [21, 24, 50]. Upon 298 
introduction to aqueous media, the polymer-rich structure of these tablets resulted in formation 299 
of gel-like layer [51]. Further acceleration to drug release could be achieved through design 300 
approach [43]. 301 
Despite the significant advances of the reported approach, it is confined to small batch 302 
manufacturing and is less suitable for large scale or continuous manufacturing. Although 303 
drying time is relatively brief, the combination of heat and water might accelerate drug 304 
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degradation particularly if hydrolysis-labile molecule is incorporated. The omittance of the 305 
drying process could be achieved by avoiding the use of solvent, however, this will involve use 306 
of high processing temperature or materials of low melting points. This highlights the 307 
importance of carefully selecting the 3D printing manufacturing approach to suit a particular 308 
active molecule and batch size. 309 
4. Conclusion 310 
We have reported a novel hybrid approach of combined temperature and solvent (water) to 311 
facilitate the additive manufacturing of immediate release tablets using simple extrusion. The 312 
proposed process was compatible with pharmaceutical grade hygroscopic polymers (PVA and 313 
PVP). We demonstrated that the starting material was compatible with a number of fillers 314 
(lactose, sorbitol and D-mannitol). The produced tablets demonstrated pharmacopeial 315 
acceptable weight and content uniformity and proved mechanically resistant. This reported 316 
hybrid approach offers significant advantages compared to other 3DP technologies:  i) 317 
replacing difficult-to-engineer FDM -compatible filament with a simpler powder or compact 318 
cylinder, ii) the use of a moderate temperature range (65-100 oC), iii) a brief drying period, and 319 
iv) avoiding the use of mechanically complicated and hard-to-clean direct extruder machinery. 320 
These novel features can provide hospital and compounding units with a simple, low-cost 321 
approach to dispense small batch of patient-customised tablets. However, for continuous 322 
manufacturing, removal of drying step, and hydrolysis labile drugs, other manufacturing 323 
approach could be considered.  324 
 325 
  326 
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Fig. 1. Equipment for TASFEX 3D printing. (a) The printer is equipped with a metal syringe surrounded 329 
by temperature-controlled heating jacket. The syringe is fitted with a luer-lock stainless steel needle, 330 
(b) The pharmaceutical ink (compressed powder) is added. The ink is then extruded by a piston pushed 331 
by computer-controlled stepper motor equipped with gear to produce (c) 3D printed tablet. 332 
Fig. 2 Photographs of 3D printed tablets based on (a1) PVA and sorbitol, (b1) PVA and lactose and 333 
(c1) PVA and D-mannitol and (d1) PVP and lactose. SEM images of (a2, b2, c2 and d2) top view, (a3, 334 
b3, c3 and d3) side view, and (a4, b4, c4 and d42) cross sections of these tablets. 335 
Fig. 3 TGA thermal degradation profiles of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), 336 
filler [ (a) sorbitol, (b) lactose and (c) D-mannitol], pharmaceutical ink (prior to addition of water) and 337 
3D printed tablets.  338 
Fig. 4 DSC thermograph of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), filler [(a) 339 
sorbitol, (b) lactose and (c) D-mannitol], pharmaceutical ink (prior to addition of water) and 3D printed 340 
tablets.  341 
Fig. 5 XRD patterns of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), filler [ (a) sorbitol, 342 
(b) lactose and (c) D-mannitol, pharmaceutical ink (prior to addition of water) and 3D printed tablets.  343 
Fig. 6 3D Printed tablet based on poly(vinylpyridine) (PVP) (A) TGA thermal degradation profiles, (B) 344 
DSC thermograph profiles, (C) XRD patterns of raw theophylline, PVP, Sodium stearyl fumarate 345 
(PRUV), lactose, pharmaceutical ink (prior to addition of water) and 3D printed tablets. 346 
Fig. 7 Impact of (a) sorbitol percentage, (b) nature of filler (sorbitol, lactose and D-mannitol), and (c) 347 
molecular weight of PVA on the in vitro dissolution of theophylline from 3D printed tablets, (d) in vitro 348 
dissolution of theophylline from 3D printed PVP based tablets (n= 3, ±SD). 349 
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Fig. 1. Equipment for TASFEX 3D printing. (a) The printer is equipped with a metal syringe surrounded by temperature-controlled heating jacket. The syringe 507 
is fitted with a luer-lock stainless steel needle, (b) The pharmaceutical ink (compressed powder) is added. The ink is then extruded by a piston pushed by 508 
computer-controlled stepper motor equipped with gear to produce (c) 3D printed tablet. 509 
  510 
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 511 
Fig. 2 Photographs of 3D printed tablets based on (a1) PVA and sorbitol, (b1) PVA and lactose and (c1) PVA and D-mannitol and (d1) PVP and lactose. SEM 512 
images of (a2, b2, c2 and d2) top view, (a3, b3, c3 and d3) side view, and (a4, b4, c4 and d42) cross sections of these tablets. 513 
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 515 
Fig. 3 TGA thermal degradation profiles of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), filler [ (a) sorbitol, (b) lactose and (c) D-mannitol], 516 
pharmaceutical ink (prior to addition of water) and 3D printed tablets.  517 
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 518 
Fig. 4 DSC thermograph of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), filler [(a) sorbitol, (b) lactose and (c) D-mannitol], pharmaceutical ink 519 
(prior to addition of water) and 3D printed tablets.  520 
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 521 
Fig. 5 XRD patterns of raw theophylline, PVA, Sodium stearyl fumarate (PRUV), filler [ (a) sorbitol, (b) lactose and (c) D-mannitol, pharmaceutical ink (prior 522 
to addition of water) and 3D printed tablets.  523 
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 524 
Fig. 6 3D Printed tablet based on poly(vinylpyridine) (PVP) (A) TGA thermal degradation profiles, (B) DSC thermograph profiles, (C) XRD patterns of raw 525 
theophylline, PVP, Sodium stearyl fumarate (PRUV), lactose, pharmaceutical ink (prior to addition of water) and 3D printed tablets. 526 
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 527 
Fig. 7 Impact of (a) sorbitol percentage, (b) nature of filler (sorbitol, lactose and D-mannitol), and (c) molecular weight of PVA on the in vitro dissolution of 528 
theophylline from 3D printed tablets, (d) in vitro dissolution of theophylline from 3D printed PVP based tablets (n= 3, ±SD). 529 
